Shanghai Universal Valuation Multiples
Discover Shanghai Universal's revenue and EBITDA valuation multiples and investment history.
Shanghai Universal Overview
About Shanghai Universal
Shanghai Universal Biotech Co Ltd is a focused on antibodies and related products. It is a professional and comprehensive antibody suppliers and antibodies experts , and has a one-stop efforts to develop a life sciences service providers.
Founded
2004
HQ
Employees
N/A
Website
Financials (FY)
EV
$218M
Valuation Multiples
Start free trial
Shanghai Universal Financials
Shanghai Universal reported last fiscal year revenue of $161M and negative EBITDA of ($2M).
In the same fiscal year, Shanghai Universal generated $30M in gross profit, ($2M) in EBITDA losses, and had net loss of ($3M).
Shanghai Universal P&L
In the most recent fiscal year, Shanghai Universal reported revenue of $161M and EBITDA of ($2M).
Shanghai Universal is unprofitable as of last fiscal year, with gross margin of 19%, EBITDA margin of (1%), and net margin of (2%).
Financial data powered by Morningstar, Inc.
Shanghai Universal Stock Performance
Shanghai Universal has current market cap of $367M, and enterprise value of $218M.
Shanghai Universal's stock price is $4.25.
Shanghai Universal has an EPS (earnings per share) of $-0.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $218M | $367M | -0.4% | - | - | - | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialShanghai Universal Valuation Multiples
Shanghai Universal trades at 1.3x EV/Revenue multiple, and (127.6x) EV/EBITDA.
Shanghai Universal Financial Valuation Multiples
As of September 5, 2026, Shanghai Universal has market cap of $367M and EV of $218M.
Shanghai Universal has a P/E ratio of (107.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Shanghai Universal Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Shanghai Universal Margins & Growth Rates
In the most recent fiscal year, Shanghai Universal reported gross margin of 19%, EBITDA margin of (1%), and net margin of (2%).
Shanghai Universal Margins
Data powered by FactSet, Inc. and Morningstar, Inc.
Shanghai Universal Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
Shanghai Universal Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all Shanghai Universal competitors and their valuation data. Start Free Trial | ||||||
Investments by Shanghai Universal
Shanghai Universal has invested in 1 company to date.
Latest investment by Shanghai Universal was on August 31st 2026. Shanghai Universal invested in Yuce Biotechnology in their Series B round.
Latest Investments by Shanghai Universal
| Description | Yuce Biotechnology is a China-based high-tech enterprise advancing single-molecule immunodiagnostic platforms for clinical applications. Through its Astra Biotech division, the company industrializes technologies for point-of-care testing, including fluorescence-based assays for disease biomarkers. Its Shanghai facility supports R&D and manufacturing for global diagnostics markets. |
| HQ Country |  |
| HQ City | Suzhou |
| Deal Date | 31 Aug 2026 |
| Round | Series B |
| Raised | undisclosed |
| Investors | Shanghai Universal; LH Ventures |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Shanghai Universal investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Shanghai Universal
| When was Shanghai Universal founded? | Shanghai Universal was founded in 2004. |
| Where is Shanghai Universal headquartered? | Shanghai Universal is headquartered in China. |
| Is Shanghai Universal publicly listed? | Yes, Shanghai Universal is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Shanghai Universal? | Shanghai Universal trades under 301166 ticker. |
| When did Shanghai Universal go public? | Shanghai Universal went public in 2021. |
| Who are competitors of Shanghai Universal? | Shanghai Universal main competitors include |
| What is the current market cap of Shanghai Universal? | Shanghai Universal's current market cap is $367M. |
| What is the current revenue of Shanghai Universal? | Shanghai Universal's last fiscal year revenue is $161M. |
| What is the current EV/Revenue multiple of Shanghai Universal? | Current revenue multiple of Shanghai Universal is 1.3x. |
| Is Shanghai Universal profitable? | No, Shanghai Universal is not profitable. |
| How many companies Shanghai Universal has acquired to date? | Shanghai Universal hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Shanghai Universal has invested to date? | As of September 2026, Shanghai Universal has invested in 1 company. |
| What was the last Shanghai Universal investment? | On 31st August 2026 Shanghai Universal invested in Yuce Biotechnology, participating in a Series B round, alongside LH Ventures. |
| In what companies Shanghai Universal invested in? | Shanghai Universal invested in Yuce Biotechnology. |
Lists including Shanghai Universal
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.